Federal agency overseeing the safety, efficacy, and quality of ~US $4 trillion worth of food, drugs, and medical technologies consumed in the United States each year. Through its ISTAND Pilot Program, FDA evaluates innovative Drug Development Tools that can accelerate clinical research. In April 2025 the agency acknowledged PGxAI’s Letter of Intent (DDT-IST-000037) for a generative-AI, multi-omics platform aimed at improving oncology-trial stratification, marking an important step in early regulatory engagement.
Academic medical center of the University of Florida, UF Health brings together six health-science colleges, two nationally ranked Shands teaching hospitals, and a constellation of research institutes. The enterprise invested a record US $1.25 billion in research during FY 2023, while the College of Medicine alone secured US $169 million in NIH awards, placing multiple clinical departments in the U.S. top 5 for federal funding. More than 28,000 clinicians, scientists, and staff deliver cutting-edge care to 3 million+ patients annually, driving breakthroughs in genomics, oncology, neuroscience, and regenerative medicine. PGxAI conducts joint studies that explore genotype-driven therapy optimisation in real-world patient cohorts.
Global data-platform company whose technology manages >1 billion patient records worldwide and underpins thousands of hospital EHRs. PGxAI deploys its multi-omics engine on InterSystems IRIS for Health to deliver sub-second genomic recommendations inside interoperable clinical workflows.
Hyperscale cloud provider operating 40 global regions and multiterabit backbone networks, unveiled at Google Cloud Next ’24. Through the top-tier Google for Startups Cloud Program, PGxAI harnesses high-performance compute clusters and TPU accelerators for large-scale model training and secure deployment.
Nationally ranked academic medical center anchored by a 605-bed Stanford Hospital and recognized among U.S. News & World Report’s top-10 hospitals for overall care. The system serves as the principal clinical site for Stanford Medicine, which attracted US $584 million in NIH funding in 2023. PGxAI applies Stanford-originated pharmaco-epigenomic insights to validate and refine its precision-medicine algorithms in complex care settings.
Azure’s trusted infrastructure spans 60 + regions and 300 + datacenters, the broadest footprint of any public cloud. Via the Microsoft for Startups Founders Hub, PGxAI leverages Azure AI tooling and DevOps pipelines to scale R&D and CI/CD globally.
Market leader holding ~92 % of the data-center GPU segment and driving record annual revenue above US $115 billion in 2024. Membership in NVIDIA Inception provides PGxAI with GPU credits and deep-learning expertise to accelerate LLM and multi-omics model development.
Premier technology law firm with 1,100 + attorneys across 17 offices and a client base exceeding 300 public and 3,000 private companies; ranked a “Recommended Firm” for patents by WIPR USA 2024. PGxAI relies on Wilson Sonsini for strategic counsel on intellectual-property protection and complex licensing.
Privacy-first genomics company operating what it bills as the world’s largest marketplace for DNA analysis apps and offering CLIA-certified whole-genome sequencing shipped to all 50 states. The platform combines end-to-end sample logistics, HIPAA-compliant cloud storage, and more than 100 third-party health reports. PGxAI integrates with Sequencing.com’s sequencing pipeline and data APIs to deliver turnkey pharmacogenomic testing for U.S. clients.